The Dilemma of Coronavirus Disease 2019, Aging, and Cardiovascular Disease Insights From Cardiovascular Aging Science

This Viewpoint discusses whether individuals should continue to take angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the context of coronavirus disease 2019 (COVID-19).

SPS commentary:

The British Cardiovascular Society (BCS) together with the British Society for Heart Failure (BSH) have released a joint statement with regards to treatment with ACEi or ARB in relation to COVID-19, advising patients should continue treatment with ACEi and ARB unless specifically advised to stop by their medical team.


JAMA Cardiology

Resource links:

Link to British Cardiovascular Society statement (19 March 2020